Top 10 Promising Companies To Watch For 2015

Top 10 Promising Companies To Watch For 2015: Cleveland BioLabs Inc.(CBLI)

Cleveland BioLabs, Inc., a biotechnology company, engages in the discovery, development, and commercialization of products for cancer treatment, and protection of normal tissues from radiation and other acute stresses. Its products include Protectan CBLB502, a radioprotectant molecule with multiple medical and defense applications for reducing injury from acute stresses, such as radiation and chemotherapy by mobilizing various natural cell protecting mechanisms, including inhibition of apoptosis, reduction of oxidative damage, and induction of factors that induce protection and regeneration of stem cells in bone marrow and the intestines; Protectan CBLB612, a modified lipopeptide mycoplasma that acts as a stimulator and mobilizer of hematopoietic stem cells to peripheral blood, providing hematopoietic recovery during chemotherapy and during donor preparation for bone marrow transplantation; and Curaxins, which are small molecules intended to destroy tumor cells by simultan eously targeting two regulators of apoptosis. The company has a strategic research partnership with Roswell Park Cancer Institute to develop its anticancer and radioprotectant drug candidates; a strategic partnership with ChemBridge Corporation to access a chemical library of 214,000 compounds; and a strategic alliance with The Cleveland Clinic Foundation (CCF). It also has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences; the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.; and CCF to evaluate its radioprotective drug candidates and their effects on intracellular and extracellular signaling pathways. The company was founded in 2003 and is headquartered in Buffalo, New York.

Advisors' Opinion:

• [By Lisa Levin]

  Cleveland BioLabs (NASDAQ! : CBLI) shares tumbled 34.67% to touch a new 52-week low of $0.74 as the company reported that BARDA has terminated negotiations related to its proposal for further development of Entolimod.

• [By Lisa Levin]

  Cleveland BioLabs (NASDAQ: CBLI) plummeted 32.65% to $0.7610 as the company reported that BARDA has terminated negotiations related to its proposal for further development of Entolimod.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-10-promising-companies-to-watch-for-2015.html